TIDMFARN
Faron Pharmaceuticals Oy
24 April 2023
Faron Pharmaceuticals Oy
("Faron or the Company")
Faron Announces Release of Research Confirming Bexmarilimab
Efficacy and Safety in MATINS Trial
-- Macrophage targeting can promote tumor stabilization in late-stage cancer
-- Bexmarilimab- induced macrophage activation with robust
stimulation of IFN-<GAMMA> and T-cell receptor signaling only
in patients with disease control
-- Data confirms that bexmarilimab therapy is well-tolerated
Press Release, April 24, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM:
FARN, First North: FARON), a clinical-stage biopharmaceutical
company focused on tackling cancers via novel immunotherap ies,
today announces the release of further insights from its Phase I/II
MATINS study, validating the efficacy and safety of the Company's
wholly owned immunotherapy, bexmarilimab, in solid tumors.
The manuscript, which is available here , indicates that
macrophage conversion, and changes in the tumor microenvironment
leading to disease control and prolonged survival in late-stage
cancer, is achieved with bexmarilimab monotherapy, and that
targeting CLEVER-1 with bexmarilimab is well-tolerated. CLEVER-1 is
an immunosuppressive receptor on macrophages leading to tumor
growth and metastases.
Bexmarilimab is a humanized anti-CLEVER-1 antibody that primes
the immune system to attack tumors.
In addition to these findings, the manuscript indicates that lo
w baseline immune activation is associated with bexmarilimab which
converts intratumoral macrophages to support adaptive immune
responses.
"We are very pleased to see that bexmarilimab is well-tolerated
and has promising antitumor activity as a single agent in
late-stage solid tumors," said Chief Scientific Officer Dr. Maija
Hollmén. "This manuscript brings together clinical safety and
efficacy data with in-depth analyses of tumor biopsies and systemic
inflammatory responses. Excitingly, it reinforces the evidence that
macrophage conversion in the tumor takes place after bexmarilimab
administration and coincides with treatment benefit."
For more information please contact:
Media Contact
Faron Pharmaceuticals
Jennifer Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
David Daley, Lindsey Neville, Renna Foufouni
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational
immunotherapy with the potential to provide immune stimulation for
treatment-resistant cancers through targeting myeloid cell
function. A novel anti-CLEVER-1 humanized antibody, bexmarilimab
targets CLEVER-1 positive (Common Lymphatic Endothelial and
Vascular Endothelial Receptor 1) tumor-associated macrophages
(TAMs) in the tumor microenvironment, converting highly
immunosuppressive M2 macrophages to immune-stimulating M1
macrophages. As an immuno-oncology therapy, bexmarilimab has
therapeutic potential in combination with other standard treatments
including immune checkpoint molecules in both solid tumors and
hematologic malignancies.
About MATINS
MATINS has demonstrated a positive safety profile in more than
200 patients treated with bexmarilimab. The study has observed an
approximate 30% clinical benefit rate in several tumor types, which
is associated with an interferon gamma (IFN-y) increase and leads
to a significant survival benefit. Moreover, responding patients
can be potentially identified using baseline IFN-y or CLEVER-1
expression. CLEVER-1 is a novel immune checkpoint, a receptor shown
to promote an immunosuppressive environment.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON),
together with its subsidiaries, is a clinical stage
biopharmaceutical group focused on building the future of
immunotherapy by harnessing the power of the immune system to
tackle cancer. Bexmarilimab , a novel anti-CLEVER-1 humanized
antibody, is its investigational immunotherapy with the potential
to remove immunosuppression of cancers through targeting myeloid
cell function. Bexmarilimab is being investigated in Phase I/II
clinical trials as a potential therapy for patients with
hematological and solid cancers in combination with other standard
treatments including immune checkpoint molecules. Faron is
headquartered in Turku, Finland. Further information is available
at www.faron.com .
Forward-Looking Statements
Certain statements in this announcement are, or may be deemed to
be, forward-looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward-looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic
and business conditions, competition, environmental and other
regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward-looking statements.
Subject to any continuing obligations under applicable law or
any relevant AIM Rule requirements, in providing this information
the Company does not undertake any obligation to publicly update or
revise any of the forward-looking statements or to advise of any
change in events, conditions or circumstances on which any such
statement is based.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFSRSSIVFIV
(END) Dow Jones Newswires
April 24, 2023 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024